Hvad er oversættelsen af " RELISTOR " på dansk?

• relistor

Eksempler på brug af Relistor på Engelsk og deres oversættelser til Dansk

What is Relistor used for?
Hvad anvendes Relistor til?

Other information about Relistor.
Andre oplysninger om Relistor.

Why has Relistor been approved?
Hvorfor blev Relistor godkendt?

Carcinogenicity studies have not been conducted with RELISTOR.
Der er ikke udført nogen cancerforsøg med Relistor.

How to store RELISTOR 6.
Sådan opbevarer du Relistor 6.

Relistor is a solution for injection.
Relistor er en injektionsvæske, opløsning.

What benefit has Relistor shown during the studies?
Hvilken fordel viser undersøgelserne, at der er ved Relistor?

Relistor is given as a subcutaneous injection.
Relistor gives som en subkutan injektion.

The Committee recommended that Relistor be given marketing authorisation.
Udvalget anbefalede, at Relistor fik markedsføringstilladelse.

RELISTOR is for use in adults aged 18 and over.
Relistor er beregnet til voksne 18 år og derover.

The following instructions explain how to inject Relistor.
Indledning Nedenstående instrukser forklarer, hvordan man skal indsprøjte Relistor.

RELISTOR 12 mg/ 0.6 ml solution for injection.
Relistor 12 mg/ 0, 6 ml injektionsvæske, opløsning.

Subcutaneous injections of RELISTOR at 150 mg/ kg/ day decreased fertility in rats.
Subkutane injektioner af Relistor på 150 mg/ kg/ dag nedsatte rotters fertilitet.

Relistor can be injected without regard to food.
Relistor kan injiceres uden hensyn til fødeindtagelse.

For the full list of all side effects reported with Relistor, see the package leaflet.
Den fuldstændige liste over kendte bivirkninger ved Relistor fremgår af indlægssedlen.

RELISTOR is given on top of your usual laxatives.
Relistor gives i tillæg til dine sædvanlige afføringsmidler.

After the needle is inserted, let go of the skin and slowly push the plunger all the way down to inject Relistor.
Slip huden, når kanylen er inde i huden, og pres langsomt stemplet helt ned for at indsprøjte Relistor.

RELISTOR 12 mg/ 0.6 ml solution for injection.
Relistor 12 mg/ 0, 6 ml injektionsvæske, opløsning til injektion.

The European Commission granted a marketing authorisation valid throughout the European Union for Relistor to Wyeth Europa Limited on 02 July 2008.
Europa- Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele den Europæiske Union for Relistor til Wyeth Europa Limited den 02 juli 2008.

Relistor is given as an injection under the skin, once every two days.
Relistor gives som en injektion under huden én gang hver anden dag.

The active substance in Relistor, methylnaltrexone bromide, is a mu-opioid receptor antagonist.
Det aktive stof i Relistor, methylnaltrexonbromid, er en mu- opioid- receptorantagonist.

RELISTOR should only be used in patients who are receiving palliative care.
Relistor bør kun anvendes til patienter, der får palliativ behandling.

By blocking these receptors, Relistor reduces the constipation due to opioids, but does not interfere with their painkilling effects.
Ved at blokere disse receptorer, reducerer Relistor konstipation, som skyldes opioider, uden at hindre midlets smertestillende virkning.

Relistor was more effective than placebo in stimulating the bowels to open.
Relistor var mere effektiv end placebo til at stimulere tarmene til at åbne sig.

In the second study, 52% of the patients receiving Relistor opened their bowels at least twice within four hours of the first four doses(32 out of 62), compared with 8% of those receiving placebo 6 out of 71.
I den anden undersøgelse åbnede tarmene sig mindst to gange inden for fire timer af de første fire doseringer for 52% af de patienter, der fik Relistor(32 ud af 62), sammenlignet med for 8% af de patienter, der fik placebo 6 ud af 71.

Relistor is a medicine that contains the active substance methylnaltrexone bromide.
Relistor er et lægemiddel, der indeholder det aktive stof methylnaltrexonbromid.

The Committee for Medicinal Products for Human Use(CHMP) decided that Relistor' s benefits are greater than its risks for the treatment of opioid-induced constipation in advanced illness patients who are receiving palliative care when response to usual laxative therapy has not been sufficient.
Udvalget for Humanmedicinske Lægemidler(CHMP) konkluderede, at fordelene ved Relistor er større end risiciene ved behandling af konstipation foranlediget af opioider hos patienter med fremskredne sygdomme, som modtager palliativ behandling, og hvis reaktioner på almindelige afføringsmidler ikke er tilstrækkelige.

Relistor was marketed the 11th of August 2008, and is not under the rules of general reimbursement.
Relistor er markedsført d. 11. august 2008, og der ydes ikke generelt tilskud.

Do not use RELISTOR after the expiry date, which is stated on the carton and vial.
Brug ikke Relistor efter den udløbsdato, der står på pakningen.

Relistor was studied in two main studies in a total of 288 patients with an advanced illness and constipation caused by opioids.
Relistor blev undersøgt i to hovedundersøgelser med i alt 288 patienter med fremskreden sygdom og konstipation som følge af opioider.

Hvordan man bruger "relistor" i en Engelsk sætning

Wyeth got three drugs approved last year -- antidepressant Pristiq, Relistor for constipation caused by narcotic painkillers, and the hemophilia drug Xyntha.

Relistor is an injection for subcutaneous use for the treatment of opioid-induced constipation in adult patients who suffer from chronic, noncancer pain.

Relistor is an opioid antagonist that works to alleviate OIC and is designed to avoid impacting the analgesic effects of the opioids.

Thanks to Dave Giles from whom I borrowed these nice shots of the Relistor piece doing its job out in the wild.

recalled Relistor injection kits because the sterile alcohol pads manufactured by Triad may be contaminated with a bacteria that could cause injuries.

Relistor (methylnaltrexone bromide) subcutaneous injection is a first-in-class treatment for opioid-induced constipation approved in more than 50 countries for patients with advanced illness.

The term pharmacokinetics of Relistor were not influenced by tree age, gender, or race differential in adult patients with a constipation, drug induced.

Therefore, it's also likely that the Relistor sNDA is approved by the FDA, which generally responds to an Adcom recommendation within 30 days.

The oral formulation of Relistor was approved by FDA this July for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain.

September 29, 2014 – The US Food and Drug Administration (FDA) approved a new indication for Relistor (methylnaltrexone) subcutaneous injection manufactured by Salix Pharmaceuticals.

Hvordan man bruger "relistor" i en Dansk sætning

Tør injektionsstedet af med spritservietten for at forberede det område af huden, hvor Relistor skal injiceres.

Relistor (Methylnal trexonbromid) 12 mg/0,6 ml injektionsvæske, opløsning til injektion.

Prisen for en dosis af Relistor er 334,95 kr., hvilket er væsentligt dyrere end de orale laksantia på markedet.

Hvis du har glemt at bruge Relistor Hvis du har glemt at tage en dosis, så tal med din læge eller apoteket så hurtigt som muligt.

Relistor bør kun anvendes til patienter, der får palliativ behandling.

De tre områder på kroppen, der anbefales til injektion af Relistor, er lår, abdomen og overarme.

Indgivelse: Relistor gives som en subkutan injektion.

Relistor® anvendes for at mindske morfinpræparaters stoppende virkning hos patienter med stærke smerter.

Relistor (Methylnaltrexonbromid) 12 mg/0,6 ml injektionsvæske, opløsning til injektion.

Hvis du får kvalme, opkastning, kulderystelser, svedafsondring, mavesmerter og/eller hurtigt hjerteslag kort tid efter indtagelse af Relistor, skal du kontakte lægen.